Vilin Bio Med MD, chairman and AGM
NSE: VILINBIOPharmaceuticals & Biotechnology
Share price at the NSE close on 27 Oct 2026. Previous close ₹50.90.
27 Oct: open ₹48.45, high ₹50.85, low ₹48.40
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹78 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.20
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.73
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,00066.7% delivered
Vilin Bio Med's chairperson and managing director is MADHU SUDHAN YADAMAKANTI REDDY, as filed for the quarter to Sep 2026. Its latest annual general meeting was on 2 Sep 2026.
Vilin Bio Med board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorMADHU SUDHAN YADAMAKANTI REDDY
- Company Secretary and Compliance OfficerNEHA LAHOTI
4 directors2 independent2 executive
- MADHU SUDHAN YADAMAKANTI REDDY · Chairperson and managing directorExecutive · joined Oct 2024 · reappointed Aug 2025 · 1 listed board · 3 committee seats
- PRASANNA LAKSHMI VENNAExecutive · joined Jan 2025 · reappointed Aug 2025 · 1 listed board
- VEERAIAH CHOWDARY KOLLAIndependent · joined Jan 2025 · reappointed Aug 2025 · 60 months as independent · 1 listed board · 1 as independent · 3 committee seats, 3 as chair
- SASIKANTH PARITALAIndependent · joined Jan 2025 · reappointed Aug 2025 · 60 months as independent · 1 listed board · 1 as independent · 3 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 15 Sep 20264 of 4 present2 independent · 33 days in between
- 12 Aug 20264 of 4 present2 independent · 1 day in between
- 10 Aug 20264 of 4 present2 independent · 26 days in between
- 14 Jul 20264 of 4 present2 independent · 16 days in between
3 earlier meetings
- 27 Jun 20264 of 4 present2 independent · 13 days in between
- 13 Jun 20264 of 4 present2 independent · 13 days in between
- 30 May 20264 of 4 present2 independent
Audit Committee
Chair VEERAIAH CHOWDARY KOLLA
SASIKANTH PARITALA, MADHU SUDHAN YADAMAKANTI REDDY
- 15 Sep 20263 of 3 present2 independent · 33 days in between
- 12 Aug 20263 of 3 present2 independent · 1 day in between
- 10 Aug 20263 of 3 present2 independent · 26 days in between
- 14 Jul 20263 of 3 present2 independent · 30 days in between
3 earlier meetings
- 13 Jun 20263 of 3 present2 independent · 13 days in between
- 30 May 20263 of 3 present2 independent · 53 days in between
- 6 Apr 20263 of 3 present2 independent
Nomination and remuneration committee
Chair VEERAIAH CHOWDARY KOLLA
SASIKANTH PARITALA, MADHU SUDHAN YADAMAKANTI REDDY
- 15 Sep 20263 of 3 present2 independent · 35 days in between
- 10 Aug 20263 of 3 present2 independent · 43 days in between
- 27 Jun 20263 of 3 present2 independent · 13 days in between
- 13 Jun 20263 of 3 present2 independent · 67 days in between
1 earlier meeting
- 6 Apr 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair VEERAIAH CHOWDARY KOLLA
SASIKANTH PARITALA, MADHU SUDHAN YADAMAKANTI REDDY
- 10 Aug 20263 of 3 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- PPKG & CoPeer-review certificate valid to Jan 2029
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Vilin Bio Med AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.
Meeting called by the tribunal, 15 Oct 2026
389 shareholders on the register on 8 Oct 2026; present: 8 promoters and 5 others; votes counted by MS. Aishwarya Chevuturi / MS. Aishwarya Chevuturi.The company's voting result
To consider and approve the Scheme of Amalgamation between Chemgenix Laboratories Private Limited (“CLPL” or “Transferor Company”) and Vilin Bio Med Limited (“VBML” or “Transferee Company”) and their respective shareholders and creditors, pursuant to the order dated September 11, 2026, passed by the Hyderabad Bench-I of the Hon’ble National Company Law Tribunal.MoreLess
Special100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 16.28% · promoters 26.00% · institutions 0.00% · other public 3.61%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 2 Sep 2026, 9 resolutions
394 shareholders on the register on 26 Aug 2026; present: 7 promoters and 2 others; votes counted by Pawan Jain / Pawan Jain & Associates.The company's voting result
- To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended March 31, 2026 together with the Board's Report and Auditors' Report thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
To appoint a Director in place of Ms. Prasanna Lakshmi Venna (DIN: 10862263), who retires by rotation at this Annual General Meeting, in terms of Section 152 of the Companies Act, 2013 and being eligible, has offered herself for re-appointment.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
- Approval to borrow Monies in Excess of Paid-up Capital and Free Reserves under Section 180(1)(c) of the Companies Act, 2013.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
- Approval to Create Charge/Security on Company Assets under Section 180(1)(a) of the Companies Act, 2013.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
- Approval for Loans, Investments, Guarantees and Securities under Sections 185 and 186 of the Companies Act, 2013.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
- Appointment of M/s Pawan Jain & Associates as Secretarial Auditors of the CompanyOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
- Approval of Material Related Party Transaction to be entered M/s Vilo Speciality Pharma Private Limited (Wholly Owned Subsidiary)Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
- Approval of Material Related Party Transaction to be entered into with M/s Axia Pharma Private Limited (Wholly Owned Subsidiary)Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
- Disclosures of Material Related Party Transactions for the Financial Year 2025-2026.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 56.00% · promoters 93.30% · institutions 0.00% · other public 7.25%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Stakes in unlisted companies
Reported in the filing for the quarter to Sep 2026.
- Unlisted stake heldAXIA PHARMA PRIVATE LIMITEDSince 16 Jul 2026
0.00% bought in the quarter; holding 100.00%, from 100.00%
- Unlisted stake heldVILO SPECIALITY PHARMA PRIVATE LIMITEDSince 23 Jul 2026
0.00% bought in the quarter; holding 100.00%, from 100.00%
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- No
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Reason and comments |
|---|---|---|---|---|---|---|
| Preferential IssuesMar 2026 | 3.38 | Working Capital | 3.27 | 1.87 | No | No Deviation |
| Preferential IssuesMar 2026 | 3.38 | Issue Expenses | 0.11 | 0.11 | No | No Deviation |